Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.47 |
| ▸ | NCOA1 | Q15788 | 1/20 | 0.47 |
| ▸ | NCOA3 | Q9Y6Q9 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
| ▸ | MITF | O75030 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.39 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4472918 | 1.00 | MAPT (0.47) | MAPTPOLBSMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL6503717 | 0.77 | MAPT (0.57) | MAPTPOLBSMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL6503720 | 0.77 | MAPT (0.57) | MAPTPOLBSMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL4770778 | 0.77 | ADORA2B (0.48) | MAPTADORA1 | |
| SCHEMBL4770769 | 0.77 | ADORA2B (0.48) | MAPTADORA1 | |
| SCHEMBL4762500 | 0.76 | MAPT (0.40) | MAPTPOLBSMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL4762507 | 0.76 | MAPT (0.40) | MAPTPOLBSMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL4771159 | 0.74 | NCOA1 (0.41) | MAPTPOLBSMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL4763392 | 0.74 | NCOA1 (0.44) | MAPTPOLBSMN1; SMN2NCOA1NCOA3 | |
| SCHEMBL4763390 | 0.74 | NCOA1 (0.44) | MAPTPOLBSMN1; SMN2NCOA1NCOA3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8349848-B2 | Pyrrolo[3,2-D]pyrimidines that are selective antagonists of A2B adenosine receptors | Dogwoof Pharmaceuticals, Inc. (US) | 2013-01-08 | — | — | US | disclosed |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC | 2009-03-26 | — | — | US | disclosed |
| US-7470697-B2 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2B adenosine receptors | ADENOSINE THERAPEUTICS, LLC (US) | 2008-12-30 | — | — | US | disclosed |
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADENOSINE THERAPEUTICS, LLC | 2008-05-29 | — | — | US | disclosed |
| WO-2008027585-A2 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADENOSINE THERAPEUTICS, LLC (US) | 2008-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080125425-A1 | Pyrrolo[3,2-D] pyrimidines that are selective antagonists of A2badenosine receptors | ADORA2B, ADORA2A, ADORA3 | MAPT 4680/4885POLB 633/4885SMN1; SMN2 3877/4885 |
| US-20090082347-A1 | PYRROLO[3,2-D]PYRIMIDINES THAT ARE SELECTIVE ANTAGONISTS OF A2B ADENOSINE RECEPTORS | ADORA2B, ADORA2A, ADORA3 | MAPT 4693/4885POLB 287/4885SMN1; SMN2 4068/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.